FDA, Acetadote

Cumberland Pharma Stock Hits 16-Month High After FDA Approves Liver Drug Regimen: Retail’s Thrilled
Shares of Cumberland Pharmaceuticals (CPIX) doubled on Tuesday morning, reaching levels not seen since March 2023, following FDA approval of a new dosing regimen for its liver drug, Acetadote. Acetadote,
FDA Approves Cumberland's New Dosing Regimen For Acetadote In Acetaminophen Overdose Treatment
Cumberland Pharmaceuticals Inc. (CPIX), a specialty pharmaceutical company, Tuesday, announced that its supplemental New Drug
New Dosing Regimen for APAP Overdose Antidote Acetadote Approved
The newly approved regimen is expected to simplify administration and potentially reduce medication errors and dose-related reactions.
Cumberland Pharma Shares Rise 56% After FDA Approves Liver Drug Acetadote
Shares of Cumberland Pharmaceuticals were trading higher in the after-hours market after the company said the Food and Drug Administration approved a supplemental new drug application for liver drug Acetadote. After the bell Monday, the company's shares had risen 56%, trading at $1.93. Volume in the after-hours market surpassed 4.4 million shares.
Cumberland announces FDA approves sNDA for Acetadote product
Pharmaceuticals announced the FDA has approved a supplemental New Drug Application for its Acetadote product. Acetadote is an
FDA APPROVES ACETADOTE® sNDA
Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on delivering high-quality products to improve patient care, announced today the FDA has approved a supplemental New Drug Application (sNDA) for its Acetadote® (N-acetylcysteine for injection) product.
Cumberland Pharmaceuticals (CPIX) Soars in Premarket Trading on FDA Approval
Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a Tennessee-based specialty pharmaceutical company, saw its stock price surge by a remarkable 95.96% to $2.43 in Tuesday’s premarket trading session. This significant jump comes after the company announced a major milestone: the FDA’s approval of a supplemental New Drug Application (sNDA) for its product Acetadote® (N-acetylcysteine for injection).
Why Is Cumberland Pharmaceuticals Stock Trading Over 100% on Tuesday?
FDA approval streamlines Acetadote dosing, enhancing safety and efficiency in treating acetaminophen-related liver injury in ...
Nashville Post2d
Cumberland Pharmaceuticals stock pops
Cumberland Pharmaceuticals saw shares of its stock soar nearly 100 percent in value on Tuesday following the Nashville-based ...
Cumberland Stock Soars 90% After FDA Approval for Acetadote Dosing Change
FDA approval of Acetadote's simplified dosing propels Cumberland Pharmaceuticals' stock to a 90% single-day surge ...
Nasdaq15d
Cumberland sNDA for Acetadote approved by FDA
The FDA approved a supplemental NDA for Acetadote, an antidote for acetaminophen overdose indicated to prevent or lessen hepatic injury after ingestion of a potentially hepatotoxic quantity of ...